Review of Rome-IV criteria for the irritable bowel syndrome: are there any basic changes?
https://doi.org/10.22416/1382-4376-2016-5-99-103
Abstract
Aim of the lecture. To analyze the changes in the Rome IV criteria of the irritable bowel syndrome (IBS) in comparison to their previous version. Summary. The term «discomfort» was withdrawn from the definition of IBS, and the phrase «pain decreases after defecation» was replaced by «pain related to defecation»; number of days when patient experience abdominal pain, required for diagnostics of this disease is changed. As in the previous version, it is recommended to estimate compliance of the patient’s symptoms to Rome criteria, though it is noted that IBS-like clinical symptoms may be attributed to other diseases (celiac sprue, chronic inflammatory bowel diseases etc.). It causes the need of the limited laboratory and instrumental investigation of the patients. The new drugs (rifaximin, lubiprostone, linaclotide etc.) are included in the treatment modes. Conclusion. Rome-IV criteria of IBS represent a certain step forward, especially regarding diagnosis and treatment of the discussed disease.
About the Authors
A. A. Sheptulin
Federal state educational government-financed institution of higher education «Sechenov First Moscow state medical university»
Russian Federation
Russian Federation
M. A. Vize-Khripunova
State educational state-funded institution of higher professional education «Ulyanovsk state university»
Russian Federation
Russian Federation
References
1. Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению больных с синдромом раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2014; 24(2):92-101
2. Ивашкин В.Т., Алексеенко С.А., Колесова Т.А. и др. Резолюция Экспертного совета, посвященного проблемам диагностики и лечения функциональных заболеваний желудочно-кишечного тракта. Рос журн гастроэнтерол гепатол колопроктол 2016; 26(4):129-30
3. Lacy B.E., Mearin F., Lin Chang, et al. Bowel disorders. Gastroenterology 2016; 150(6):1393-407.
4. Layer P., Andresen V., Pehl C., et al. Guideline irritable bowel syndrome: definition, pathophysiology, diagnosis and therapy. Joint Guideline of the German Society for Digestive and Metaboloc Diseases (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM). Z Gastroenterol 2011; 49:237-9.
5. Longstreth G.F., Thompson W.G., Chey W.D. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
6. Mearin F. Lower gastrointestinal bowel disorders // AGA Institute Rome Foundation lectureship: the launching of Rome IV: what’s new and why? Digestive Disease Week, San Diego, 2016. Oral presentation.
7. Ruepert L., Quartero A.J., de Wit N.J., et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. The Cochrane Collaboration. The Cochrane Library 2013, Issue 3.
Review
For citations:
Sheptulin A.A., Vize-Khripunova M.A. Review of Rome-IV criteria for the irritable bowel syndrome: are there any basic changes? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(5):99-103. (In Russ.) https://doi.org/10.22416/1382-4376-2016-5-99-103
Views:
2593
Email this article 
